StemCell Therapy

NEW YORK, NY--(Marketwired - April 19, 2017) - Planda Biotechnology (PLPL) recently presented investors with its outlook for 2017 and a number of milestones that the company plans to accomplish in 2017. Planda's plans are certainly aggressive and representative of the new Chief Operating Officer (COO) -- someone we feel is ideally suited to move the company forward. It didn't take long at all for the new COO, Callum Cottrell-Duffield, to put his stamp on the company's future.

Three weeks ago Planda named Callum Cottrell-Duffield as its new COO, a role that will have him running the day-to-day operations of the company. In the time since being named COO, he has put together a plan to not only get Planda back on track, but to also move it aggressively into the future. With Planda shifting from purely a research and development biotechnology company to a company that is more focused on operations and sales, Callum Cottrell-Duffield is the ideal person to run Planda's day-to-day activity.

After all, he has been there from the beginning where he helped to prepare the company's 8,000-acre tea estate to grow, harvest and produce Planda's signature product, the highly bioavailable Phytofare Catechin Complex. Last year when that signature product was available for mass production and ready to market on a much broader scale, it was Callum Cottrell-Duffield who led the company's sales and marketing team. He has traveled throughout Africa, the United States, Europe, Asia and South America to tell the Planda story, and he has become the face of the company to the industry and to the large buyers who are either current clients or interested in developing a relationship with Planda worldwide.

In the company's latest news release, the COO highlighted several areas where he expects to see improvement and areas where Planda can realize growth. Among those items, Callum Cottrell-Duffield said that he (i) has placed getting the company "current" with its SEC filings at the top of his agenda, (ii) expects to increase production and to continue growing sales with Planda's existing customers as well as gaining traction in the market, which should lead to the addition of new customers all in an effort to make Planda cash flow positive and profitable by the end of 2017, (iii) recently signed a financing agreement that will provide the necessary capital to see the company through until it becomes cash flow positive.

With the appointment of Callum Cottrell-Duffield to COO, the company's CEO, Roger Baylis-Duffield, can now focus his efforts as a scientist on spearheading the company's clinical trials and developing new products for Planda to market. In the company's research and development efforts, the CEO will be busy with a number of major studies this year.

According to the COO, Planda's work in the clinic will include:

Additionally, Planda has granted a research license to Protext Mobility to develop pharmaceutical applications involving Phytofare. Protext will be conducting a human study using Phytofare to regulate glucose levels in Type 2 diabetics as well as, taking over the research to establish a platform for producing non-psychoactive Cannabis. Planda states that the plan for Protext is to produce a Phytofare complex containing bioavailable cannabinoids, cannabinoid acids, and polyphenols that will be formulated into an oral delivery system.

Needless to say, with success in these studies, these are all areas where Planda could develop much-needed products that could, in turn, drastically improve the company's bottom line. For a full look into the COO's agenda for 2017, read Planda's latest news release here:

http://finance.yahoo.com/news/plandai-biotechnology-chief-operating-officer-162043100.html

About Stock Market Media Group

Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles.

We may from time to time include our own opinions about our featured companies, their businesses, markets and opportunities. Any opinions we may offer are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers and viewers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any company are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: http://www.sec.gov. We also recommend as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.

Read More

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications are not a recommendation to buy or sell a security.

Section 17(b) of the 1933 Securities and Exchange Act requires publishers who distribute information about publicly traded securities for compensation, to disclose who paid them, the amount, and the type of payment. In order to be in full compliance with the Securities Act of 1933, Section 17(b), we are disclosing that SMMG is compensated $5,000 per month by Plandai Biotechnology for content development. Neither SMMG nor anyone associated with it owns shares in PLPL.

For more information: http://www.stockmarketmediagroup.com.

See the original post here:
Plandai Biotechnology Sets Aggressive Agenda for 2017 - Yahoo Finance

This entry was posted on April 20, 2017 at 8:41 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |